Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Zalcitabine

M J Shelton1, A M O'Donnell, G D Morse

  • 1American Foundation for AIDS Research, Center for Clinical Pharmacy Research, Buffalo, NY.

The Annals of Pharmacotherapy
|April 1, 1993
PubMed
Summary
This summary is machine-generated.

Zalcitabine (ddC) combined with zidovudine (ZDV) shows potential in treating HIV by boosting CD4+ cell counts in ZDV-naive patients. However, further controlled studies are needed to confirm efficacy and long-term outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The implications of vaping for the anaesthetist.

BJA education·2021
Same author

Clinical pharmacology quality assurance for HIV and related infectious diseases research.

Clinical pharmacology and therapeutics·2013
Same author

Investigation of L-type Ca(2+) current in the aganglionic bowel segment in Hirschsprung's disease.

Neurogastroenterology and motility·2012
Same author

Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected Ugandans.

HIV medicine·2011
Same author

Survey of the fatty acid composition of retail milk differing in label claims based on production management practices.

Journal of dairy science·2010
Same author

Hot topic: Enhancing omega-3 fatty acids in milk fat of dairy cows by using stearidonic acid-enriched soybean oil from genetically modified soybeans.

Journal of dairy science·2010
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
Same journal

RSVpreF: A Vaccine for the Respiratory Syncytial Virus.

The Annals of pharmacotherapy·2026
Same journal

Severe Acute Hepatitis Induced by Combined Rosuvastatin and Ticagrelor Therapy Post-PCI: The Challenges of Multi-Drug DILI Diagnosis.

The Annals of pharmacotherapy·2026
Same journal

Modified vs Full Lead-in Dose Apixaban and Rivaroxaban for Treatment of Acute Venous Thromboembolism.

The Annals of pharmacotherapy·2026
Same journal

A Comparison of Phenobarbital Dosing Strategies for the Treatment of Alcohol Withdrawal Syndrome.

The Annals of pharmacotherapy·2026
See all related articles

Area of Science:

  • Pharmacology
  • Virology
  • Clinical Medicine

Background:

  • Zalcitabine (2'3'-dideoxycytidine, ddC) is a nucleoside analog with antiviral properties.
  • Its use in HIV treatment is often considered in combination therapy.
  • Understanding its pharmacokinetic and clinical profile is crucial for optimizing HIV management.

Purpose of the Study:

  • To comprehensively review the chemistry, intracellular metabolism, pharmacokinetics, and clinical trial data of zalcitabine (ddC).
  • To evaluate the efficacy and safety of ddC in combination with zidovudine (ZDV) for HIV infection.

Main Methods:

  • Literature review of English-language articles and conference proceedings using keywords: zalcitabine, 2'3'-dideoxycytidine, and ddC.
  • Inclusion of manufacturer's package insert and available Phase I and Phase I/II studies.

Related Experiment Videos

  • Analysis of uncontrolled studies and expanded-access program data, focusing on surrogate markers like CD4+ counts and p24 antigen levels.

    • Main Results:

    • The FDA approved ddC in combination with ZDV for HIV patients with CD4+ counts ≤300 cells/mm³ experiencing deterioration.
    • ddC/ZDV demonstrated increased CD4+ counts and reduced p24 antigen levels in ZDV-naive patients.
    • Peripheral neuropathy occurred in 17-31% of patients receiving ddC, with varying severity.

    Conclusions:

    • ddC in combination with ZDV may enhance CD4+ cell response compared to ZDV monotherapy in ZDV-naive HIV patients.
    • Controlled studies are necessary to validate these findings and establish statistical significance.
    • The efficacy of ddC/ZDV in patients previously treated with ZDV monotherapy remains unclear.